Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 13;13(3):314-23.
doi: 10.1016/j.chom.2013.02.008.

Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection

Affiliations

Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection

Suman R Das et al. Cell Host Microbe. .

Abstract

Human influenza A virus (IAV) vaccination is limited by "antigenic drift," rapid antibody-driven escape reflecting amino acid substitutions in the globular domain of hemagglutinin (HA), the viral attachment protein. To better understand drift, we used anti-hemagglutinin monoclonal Abs (mAbs) to sequentially select IAV escape mutants. Twelve selection steps, each resulting in a single amino acid substitution in the hemagglutinin globular domain, were required to eliminate antigenicity defined by monoclonal or polyclonal Abs. Sequential mutants grow robustly, showing the structural plasticity of HA, although several hemagglutinin substitutions required an epistatic substitution in the neuraminidase glycoprotein to maximize growth. Selecting escape mutants from parental versus sequential variants with the same mAb revealed distinct escape repertoires, attributed to contextual changes in antigenicity and the mutation landscape. Since each hemagglutinin mutation potentially sculpts future mutation space, drift can follow many stochastic paths, undermining its unpredictability and underscoring the need for drift-insensitive vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Antigenic Map of Sequential Variants
(A) The antigenicity of SEQ variants was determined by measuring the relative binding affinities of a panel of 60 mAbs via RIA. Black shows equivalent binding to mutant and WT viruses; gray shows reduced affinity (2- to 4-fold); white shows greatly reduced affinity. (B) Three-dimensional model of HA rendered by PyMOL software as a solid surface looking at top and side of the trimeric molecule (using PR8 HA crystal structure 1RVX). Amino acid substitutions in escape mutants are indicated by color and label. Green shows same substitutions when selected with PR8, blue shows same amino acid position but a new substitution, and red shows new position. (C) Three-dimensional model of NA rendered by PyMOL software as a solid surface looking at top (top panel) and membrane proximal (bottom panel) aspects of the tetramer molecule (using H5N1 NA crystal structure 2HTY). NA active sites (118, 151, 152, 224, 227, 276, 292, and 371) are labeled in red and substitution G357S (H5N1 NA crystal structure 2HTY numbering) that is present in SEQ-8, SEQ-9, and SEQ-10 and decreases NA activity in green. Also see Figure S1.
Figure 2
Figure 2. Sequential Variants Acquire Epistatic Changes in NA to Optimize Receptor Avidity
(A) NA activities of HAU-normalized viruses ± detergent to dissociate viral glycoproteins were determined using a small fluorogenic substrate. (B) NA activities of PR8, SEQ-4, SEQ-8, and SEQ-12 normalized to the amount of NA protein in virions as determined by western blot. (C) Ratios of NA/HA protein content in virions determined by immunoblotting. (D) Receptor binding avidities of SEQ- variants were measured, determining the amount of RDE required to abrogate agglutination of turkey RBCs. Data are represented as mean ± SEM.
Figure 3
Figure 3. Locating H17-L2 and H17-L10 Escape Substitutions
Three-dimensional model of HA rendered by PyMOL software as a solid surface looking at top and side of the trimeric molecule (using PR8 HA crystal structure 1RVX). Amino acid substitutions in sequential variants are labeled in blue. Escape mutants of H17-L10 and H17-L2 that are present in both PR8 and SEQ-7 repertoire are labeled in red. Green shows substitutions exclusively in PR8 escape repertoire, magenta shows substitutions exclusively in SEQ-7 repertoire, and yellow shows substitutions exclusively in SEQ-8 repertoire. See also Table 3 and Table S3.
Figure 4
Figure 4. Antigenic Evolution Is Context Specific
(A) TCID50 titers of WT and mutant viruses rescued (P0 passage) after eight-plasmid transfection in 293T cells. (B) TCID50 titers of WT and mutant viruses rescued (P1-M passage) after amplifying in MDCK cells. (C) TCID50 titers of WT and mutant viruses rescued (P1-E passage) after amplifying in MDCK cells. All the experiments were performed in quadruplet, and the p values were calculated using Prism software (Student’s t test). (D and E) Binding affinities of H17-L10 and H17-L2 to PR8, PR8-D225Y, SEQ-7, and SEQ-7-D225Y were calculated by ELISA using detergent-disrupted viruses. All the experiments were done in quadruplicate, and dissociation constants were calculated using Prism software. All avidities reported demonstrated excellent fit for one site binding with Hill slope curve fitting (R2 values > 0.98). Data are represented as mean ± SEM. See also Table S2.

References

    1. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell. 1982;31:417–427. - PubMed
    1. Cleveland SM, Taylor HP, Dimmock NJ. Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect. 1997;118:149–154. - PMC - PubMed
    1. Cobey S, Pascual M. Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition. J Theor Biol. 2011;270:80–87. - PMC - PubMed
    1. Das SR, Puigbò P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010;6:e1001211. http://dx.doi.org/10.1371/journal.ppat.1001211. - DOI - PMC - PubMed
    1. Das SR, Hensley SE, David A, Schmidt L, Gibbs JS, Puigbò P, Ince WL, Bennink JR, Yewdell JW. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci USA. 2011;108:E1417–E1422. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data